XOB
XOB, also known as ASR-6001 or as N-[(4-phenylbutoxy)hexyl]-4-bromo-2,5-dimethoxyphenethylamine, is a serotonin 5-HT 2A receptor antagonist and voltage-gated sodium channel (VGSC) blocker of the phenethylamine and 2C families.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
XOB, also known as ASR-6001 or as N-[(4-phenylbutoxy)hexyl]-4-bromo-2,5-dimethoxyphenethylamine, is a serotonin 5-HT 2A receptor antagonist and voltage-gated sodium channel (VGSC) blocker of the phenethylamine and 2C families. It is a derivative of 2C-B in which the amine-containing side chain has been extended with the same long group found in salmeterol.
The drug is of relatively low potency as a serotonin 5-HT 2A receptor antagonist. It shows modest selectivity for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2B and 5-HT 2C receptors. XOB was accidentally found to have local anesthetic properties upon contact with human skin, which led to the elucidation of its sodium channel-blocking activity.
XOB was developed in part by researchers at the Alexander Shulgin Research Institute (ASRI).
See also
Substituted methoxyphenethylamine 2C (psychedelics) Serotonin 5-HT 2A receptor antagonist Evenamide
External links
XOB - Isomer Design
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371845457 under CC BY-SA 4.0; modifications have been made.